GlassScriptPhysician profile
Alexander Zeno Weber
NPI 1386095578
$3,092.21
in general payments reported to CMS, 2019-2025
36 companies · $788 in 2025
The $788 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $107 · 2021: $131 · 2022: $429 · 2023: $732 · 2024: $649 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,168.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $801.22 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $277.94 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $236.41 | 2021-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $233.18 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $202.86 | 2019-2025 | |
| Glaxosmithkline, LLC. | $151.24 | 2020-2025 | Arexvy, Shingrix, Bexsero |
| Allergan, INC. | $120.29 | 2019 | |
| Phathom Pharmaceuticals, INC. | $105.00 | 2025 | Voquezna |
| Exact Sciences Corporation | $97.66 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $94.65 | 2019-2025 | Spravato |
| Stryker Corporation | $94.23 | 2025 | Blueprint Patient Specific Instrumentation |
| Amgen INC. | $59.36 | 2019-2025 | Otezla, Repatha, Repatha |
| Axsome Therapeutics, INC. | $58.46 | 2023-2025 | Auvelity |
| Corium, LLC | $51.44 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $50.31 | 2022-2023 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $44.98 | 2024 | Gemtesa |
| Medtronic, INC. | $38.05 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.48 | 2022-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $36.15 | 2023 | Quviviq |
| Cranial Technologies, INC | $30.24 | 2023-2025 | Doc Band |
| Biohaven Pharmaceutical Holding Company LTD. | $25.45 | 2022 | |
| Nevro Corp. | $23.93 | 2023 | Senza |
| Abbott Laboratories | $22.52 | 2025 | Freestyle Libre 3 |
| Depuy Synthes Sales INC. | $21.33 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.93 | 2024 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.27 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $17.25 | 2020 | |
| Phadia US INC. | $16.57 | 2023 | Immunocap |
| Tris Pharma INC | $16.41 | 2024 | Dyanavel Xr |
| Novartis Pharmaceuticals Corporation | $15.51 | 2025 | |
| Baxter Healthcare | $13.91 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Shire North American Group INC | $13.87 | 2019 | |
| Sanofi Pasteur INC. | $12.68 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.20 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.15 | 2021 | |
| Lundbeck LLC | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.